Robert L. Coleman, MD, on Secondary Surgical Cytoreduction Followed by Chemotherapy for Ovarian Cancer

Posted: Wednesday, June 6, 2018

Robert L. Coleman, MD, of The University of Texas MD Anderson Cancer Center, discusses phase III study findings on secondary surgical cytoreduction followed by platinum-based combination chemotherapy, with or without bevacizumab, in platinum-sensitive, recurrent ovarian cancer.